PALATINE, Ill., June 6, 2011 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) announced today receipt from the United States Patent and Trademark Office (“USPTO”) of a Notice of Allowance for a non-provisional patent application related to our abuse deterrent Aversion® Technology platform. A U.S. patent relating to this Notice of Allowance will be granted after the Company pays the required fees. Upon issuance, this patent will be the third U.S. patent covering our Aversion® Technology and our opioid analgesic product candidates and broadens our patent coverage to include other abused drug classes such as stimulants and benzodiazepines.
